CN117940126A - 用于冷吡啉相关周期性综合征(caps)的治疗 - Google Patents
用于冷吡啉相关周期性综合征(caps)的治疗 Download PDFInfo
- Publication number
- CN117940126A CN117940126A CN202280059495.8A CN202280059495A CN117940126A CN 117940126 A CN117940126 A CN 117940126A CN 202280059495 A CN202280059495 A CN 202280059495A CN 117940126 A CN117940126 A CN 117940126A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- formula
- indacen
- hexahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 56
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 230000000737 periodic effect Effects 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 142
- 150000003839 salts Chemical class 0.000 claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 50
- -1 t-butoxycarbonyl Chemical group 0.000 claims description 123
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 40
- 229910005965 SO 2 Inorganic materials 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 229940124530 sulfonamide Drugs 0.000 claims description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 19
- 150000001408 amides Chemical class 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000004001 thioalkyl group Chemical group 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 229960001375 lactose Drugs 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229920002148 Gellan gum Polymers 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 239000000216 gellan gum Substances 0.000 claims description 4
- 235000010492 gellan gum Nutrition 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- YKRLMZKCVQTOAZ-NSCUHMNNSA-N (e)-prop-1-ene-1-sulfonamide Chemical compound C\C=C\S(N)(=O)=O YKRLMZKCVQTOAZ-NSCUHMNNSA-N 0.000 claims description 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- YKZWBJPYTMGHCE-CALJPSDSSA-M CN(C(/C=C/S(=O)(=O)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O)(C)C)C.[Na+] Chemical compound CN(C(/C=C/S(=O)(=O)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O)(C)C)C.[Na+] YKZWBJPYTMGHCE-CALJPSDSSA-M 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- MKVNWSAVCOMAJY-KXBZDOTHSA-M potassium [(E)-2-[(2R)-1,2-dimethylpyrrolidin-2-yl]ethenyl]sulfonyl-(1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyl)azanide Chemical compound CN1[C@@](CCC1)(C)/C=C/S(=O)(=O)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[K+] MKVNWSAVCOMAJY-KXBZDOTHSA-M 0.000 claims description 3
- ZESFSERKOVROJT-KXBZDOTHSA-M sodium [(E)-2-[(2R)-1,2-dimethylpyrrolidin-2-yl]ethenyl]sulfonyl-(1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyl)azanide Chemical compound CN1[C@@](CCC1)(C)/C=C/S(=O)(=O)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] ZESFSERKOVROJT-KXBZDOTHSA-M 0.000 claims description 3
- ZESFSERKOVROJT-YPXYOWDLSA-M sodium [(E)-2-[(2S)-1,2-dimethylpyrrolidin-2-yl]ethenyl]sulfonyl-(1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyl)azanide Chemical compound CN1[C@](CCC1)(C)/C=C/S(=O)(=O)[N-]C(NC1=C2CCCC2=CC=2CCCC1=2)=O.[Na+] ZESFSERKOVROJT-YPXYOWDLSA-M 0.000 claims description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 241000978776 Senegalia senegal Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- 229960000878 docusate sodium Drugs 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 229960000540 polacrilin potassium Drugs 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract description 32
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract description 32
- 239000003112 inhibitor Substances 0.000 abstract description 28
- 238000011161 development Methods 0.000 abstract description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 34
- 229940079593 drug Drugs 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 102000003777 Interleukin-1 beta Human genes 0.000 description 20
- 108090000193 Interleukin-1 beta Proteins 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000002757 inflammatory effect Effects 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 7
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 7
- 102000003810 Interleukin-18 Human genes 0.000 description 7
- 108090000171 Interleukin-18 Proteins 0.000 description 7
- 229960004238 anakinra Drugs 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- HUUSXLKCTQDPGL-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea Chemical compound CC(C)(O)C1=COC(S(=O)(=O)NC(=O)NC=2C=3CCCC=3C=C3CCCC3=2)=C1 HUUSXLKCTQDPGL-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 239000003430 antimalarial agent Substances 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 5
- 229960004099 azithromycin Drugs 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 4
- 229940124291 BTK inhibitor Drugs 0.000 description 4
- 101150071146 COX2 gene Proteins 0.000 description 4
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 108010008165 Etanercept Proteins 0.000 description 4
- 102100037387 Gasdermin-A Human genes 0.000 description 4
- 101001026276 Homo sapiens Gasdermin-A Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 101150000187 PTGS2 gene Proteins 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003096 antiparasitic agent Substances 0.000 description 4
- 229940125687 antiparasitic agent Drugs 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 229940046844 aromatase inhibitors Drugs 0.000 description 4
- 229940125388 beta agonist Drugs 0.000 description 4
- 102000023732 binding proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960001338 colchicine Drugs 0.000 description 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000007580 dry-mixing Methods 0.000 description 4
- 229960000403 etanercept Drugs 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000005906 Imidacloprid Substances 0.000 description 3
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 229960001838 canakinumab Drugs 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 229950008454 favipiravir Drugs 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 229940056881 imidacloprid Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 208000005989 Arenaviridae Infections Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000712890 Junin mammarenavirus Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- RRBZUCWNYQUCTR-UHFFFAOYSA-N 2-(aminoazaniumyl)acetate Chemical compound NNCC(O)=O RRBZUCWNYQUCTR-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SGLOJCJAPYMDCM-UHFFFAOYSA-N 2-hexylbenzene-1,3-dicarboxylic acid Chemical compound CCCCCCC1=C(C(O)=O)C=CC=C1C(O)=O SGLOJCJAPYMDCM-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- LQFRYKBDZNPJSW-UHFFFAOYSA-N 3-methylsulfonylpropanenitrile Chemical compound CS(=O)(=O)CCC#N LQFRYKBDZNPJSW-UHFFFAOYSA-N 0.000 description 1
- DJTINRHPPGAPLD-DHDCSXOGSA-N 4-[(z)-[4-oxo-2-sulfanylidene-3-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1\C=C/1C(=O)N(CC=2C=C(C=CC=2)C(F)(F)F)C(=S)S\1 DJTINRHPPGAPLD-DHDCSXOGSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 101710115313 Pyrin domain-containing protein 3 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005325 aryloxy aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 108091008878 cytoplasmic PRRs Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001975 deuterium Chemical class 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229960004985 lumefantrine Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- FNPPHVLYVGMZMZ-XBXARRHUSA-N necrosulfonamide Chemical compound COC1=NC=CN=C1NS(=O)(=O)C(C=C1)=CC=C1NC(=O)\C=C\C1=CC=C([N+]([O-])=O)S1 FNPPHVLYVGMZMZ-XBXARRHUSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 description 1
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及用于治疗冷吡啉相关周期性综合征(CAPS)的式(I)化合物的开发。具体地,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的NLRP3抑制剂或其药学上可接受的盐。发明还涉及用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐的药物组合物。
Description
技术领域
本发明涉及用于治疗冷吡啉(Cryopyrin)相关周期性综合征(CAPS)的式(I)化合物的开发。具体地,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的NLRP3抑制剂或其药学上可接受的盐。发明还涉及用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐的药物组合物。
背景技术
核苷酸结合寡聚化结构域(NOD)样受体家族,含pyrin结构域蛋白3(NLRP3或NALP3)炎症小体是粘膜白细胞介素(IL)-1β的主要来源,并且炎症小体大多受到炎症相关应激的多个方面的激活。NLRP3是一种感知外源和内源性危险信号的胞质模式识别受体(PRR)。NLRP3蛋白由三个结构域组成:富含亮氨酸的重复结构域(LRR)、含有半胱天冬酶激活和募集结构域(CARD)的NOD(NACHT)和pyrin结构域(PYD)。激活后,NLRP3通过PYD-PYD相互作用寡聚化并触发含有CARD的接头凋亡相关斑点样蛋白(ASC)的组装。ASC原纤维组装成称为ASC斑点的大结构,并募集半胱天冬酶-1前体,导致其自身蛋白水解激活。激活的半胱天冬酶-1能够切割IL-1β前体和IL-18前体,以产生炎性细胞因子IL-1β和IL-18(Guo等人,2015;Dinarello等人,2012)。
NLRP3炎症小体参与不同类型的疾病为设计靶向NLRP3炎症小体的药物提供了新的途径。到目前为止,NLRP3相关疾病的临床治疗分别用IL-1β抗体或重组IL-1β受体拮抗剂(例如卡那单抗(Canakinumab)和阿那白滞素(anakinra))靶向IL-1β。此外,一些小分子化合物已经在体外对NLRP3炎症小体激活显示出抗炎作用,包括MCC950、β-羟基丁酸酯(BHB)、Bay 11-7082、二甲基亚砜(DMSO)和I型干扰素。然而,这些抑制剂大多是相对非特异性的并且具有低疗效。对于靶向IL-1β的抑制剂,需要注意的是,IL-1β分泌并不是NLRP3炎症小体激活的唯一产物;相反,其他促炎细胞因子,包括高迁移率组蛋白B1(HMGB1)和IL-18,可能参与这些疾病的发病机制。此外,IL-1β可以通过炎症小体非依赖性途径或其他炎症小体产生。因此,靶向IL-1β的抑制剂除了阻止NLRP3炎症小体本身的激活外,还可能导致意想不到的免疫抑制作用。针对NLRP3炎症小体的药理学抑制剂可能是治疗NLRP3相关疾病的最佳选择。(Yang等人,2019)。
冷吡啉相关周期性综合征(CAPS)是一种罕见的异质性自身炎症性疾病家族,以IL-1β介导的全身炎症和涉及皮肤、关节、中枢神经系统和眼睛的临床症状为特征。CAPS与NLRP3中的激活突变有关,其中约200种突变已被定义。虽然一些突变被归类为良性突变,并且没有有害的临床表型,但大约有100种报告的突变导致慢性促炎表现。CAPS分为三个严重程度不断增加的临床亚组:家族性感冒自身炎症综合征(FCAS)、Muckle-Wells综合征(MWS)和新生儿多系统炎症疾病(NOMID),也称为慢性婴儿神经皮肤和关节综合征(CINCA)(Booshehri等人,2019)。携带CAPS中出现的NLRP3突变形式的小鼠在新生儿期死亡,并且循环IL-1β和IL-18的浓度增加(Coll等人2015)。先前证明MCC950在MWS的小鼠模型中抑制NLRP3的激活。与健康对照组相比,来自具有低外显率NLRP3变体(Q703K和V198M)的患者的外周血单核细胞(PBMC)在炎症小体激活后显示出增强的IL-1β水平。此外,IL-1β的释放已被证明是NLRP3依赖性的,因为它被MCC950阻断(Schuh等人,2019)。IL-1受体拮抗剂阿那白滞素通常用于控制该综合征的症状,但当停止治疗时,患者复发。
在1期和2期发展的不同阶段,存在靶向NLRP3炎症小体的各种试剂。(Freeman等人,2020)。MCC950、CY-09、OLT1177、曲尼司特、冬凌草甲素、NT-0167等试剂显示出良好的治疗性质,因为它们直接靶向NLRP3本身,而不是NLRP3炎症小体激活的上游/下游的其他成分(NEK7、ASC、半胱天冬酶-1或IL-1β)。此外,这些抑制剂正在临床实践中使用,或正在II期临床试验中进行研究,已显示出相对较高的安全性(Yang等人,2019)。
先天免疫细胞中的NLRP3被病原体相关分子模式和死亡相关分子模式激活。由此产生的NLRP3炎症小体激活半胱天冬酶-1,依次裂解并释放IL-1b和IL-18。NLRP3炎症小体抑制剂具有消除包括CAPS的IL-1介导的疾病病理的潜能。
所有目前的治疗方法都局限于可注射生物制品,这些可注射生物制品通常具有有限的中枢神经系统(CNS)穿透,中枢神经系统(CNS)穿透在患有严重CNS疾病的NOMID患者中尤为重要。因此,作为靶向IL-1的生物制品的替代品,对靶向性更强、优选小分子的化合物的临床需求仍未得到满足。
发明内容
在实施方案中,本发明提供适合用于治疗和预防冷吡啉相关周期性综合征(CAPS)的式(I)的治疗性化合物或其药学上可接受的盐。
在另一实施方案中,本发明提供用于治疗和预防冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐和药学上可接受的赋形剂的药物组合物。
在又一实施方案中,本发明提供适合用于治疗和预防冷吡啉相关周期性综合征(CAPS)的单独施用或者组合施用的式(I)的治疗性化合物和其药学上可接受的盐。
在进一步的实施方案中,本发明提供式(I)化合物或其药学上可接受的盐用于治疗冷吡啉相关周期性综合征(CAPS)的用途。
在另一实施方案中,本发明提供使用式(I)化合物或其药学上可接受的盐的药物组合物治疗冷吡啉相关周期性综合征(CAPS)的方法。
在下文中进一步公开本发明的以上和其他实施方案。
本发明提供用于预防和治疗冷吡啉相关周期性综合征(CAPS)和相关疾病的式(I)的治疗性化合物或其药学上可接受的盐。本发明还涉及可用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或药学上可接受的赋形剂的药物组合物。
具体实施方式
定义:
术语“治疗(treatment)”或“治疗(treat)”是指减缓、停止或延迟患者的疾病或临床症状的进展,如疾病、病症或病状的临床或诊断症状的减少或消除所证明的。
术语“对象”是指哺乳动物。
术语“有效量”在上下文中是指施用足以具有期望效果的药物的量。
“患者”包括人和动物两者。“哺乳动物”意指人和其它哺乳动物。
术语“预防”是指首先阻止对象患上病症或疾病。
“对象”是哺乳动物,优选人类,但也可以是需要兽医治疗的动物,例如,伴侣动物(例如,狗、猫等)、农场动物(例如,牛、羊、猪、马等)和实验室动物(例如,大鼠、小鼠、豚鼠等)。
如本文所用,“治疗”包括部分地或基本上实现以下结果中的一个或多个:部分地或完全地降低疾病、病症或综合征的程度。延迟、抑制或预防疾病、病症或综合征的进展包括例如延迟、抑制或预防冷吡啉相关周期性综合征(CAPS)的进展。
本发明描述了治疗患有冷吡啉相关周期性综合征(CAPS)的对象的方法。
在实施方案中,本发明提供适用于治疗冷吡啉相关周期性综合征(CAPS)的式(I)化合物或其药学上可接受的盐。
在进一步的实施方案中,本发明提供式(I)化合物或其适合的药物组合物用于治疗冷吡啉相关周期性综合征(CAPS)的用途。
方法包括向对象施用治疗有效量的根据式(I)的化合物,
其互变异构形式、其立体异构体;其对映异构体;其代谢物;其氘类似物;其药学上可接受的盐;以及含有它们的药物组合物或其混合物,
其中
X是O、NH或N-R3其中R3在每次出现时独立地表示氢,羟基,卤素,硝基,氰基,卤代烷基,任选取代的选自以下的基团:(C1-C10)烷基、(C1-C10)烷氧基、(C3-C10)环烷基、(C2-C10)烯基、(C2-C10)炔基、SO2(C1-C6)烷基、硫醇基、硫代烷基、硫代烷氧基、SO(C1-C6)烷基、苄基、芳基、杂芳基、杂环基;
Y是O、S;
R1在每次出现时独立地表示氢,卤素,卤代烷基,氰基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C2-C6)烯基、(C2-C6)炔基、(C1-C6)烷氧基、(C3-C7)环烷基、(C1-C6)烷基SO2(C1-C6)烷基、(C1-C6)烷基N(C1-C6)烷基、(C1-C6)烷基N(C3-C7)环烷基、芳基、杂芳基、杂环基、苄基、叔丁氧基羰基、NH(C1-C6)烷基、N((C1-C6)烷基)2、NH(C2-C6)烯基、N((C2-C6)烯基)2、-N-杂环基、N(C1-C6)烷基-杂环基、NR’R”、硫醇基、巯基烷基、SO2(C1-C6)烷基、SO2(C3-C7)环烷基、SO2-芳基、SO2-杂环基、(C1-C6)硫代烷基、(C1-C6)硫代烷氧基、(C1-C6)烷基SO2NH2、-CONH2、-CO(C1-C6)烷基、-CO(C1-C6)卤代烷基、-CO-芳基、-CO-杂芳基、-CO-杂环基、4至7元杂环、7至14元双环杂环体系、任选地具有一个或多个杂原子的桥环或螺环体系;
在实施方案中,R1表示:
n独立地选自整数0至3;
R’、R”、R1’、R1”、R2’和R2”中的每一个在每次出现时独立地表示氢,卤素,卤代烷基,氰基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C2-C6)烯基、(C2-C6)炔基、(C1-C6)烷氧基、(C3-C7)环烷基、(C1-C6)烷基SO2(C1-C6)烷基、(C1-C6)烷基N(C1-C6)烷基、(C1-C6)烷基N(C3-C7)环烷基、芳基、杂芳基、杂环基、苄基、叔丁氧基羰基、硫醇基、巯基烷基、SO2(C1-C6)烷基、SO2(C3-C7)环烷基、SO2-芳基、SO2-杂环基、(C1-C6)硫代烷基、(C1-C6)硫代烷氧基、(C1-C6)烷基SO2NH2、-CONH2、-CO(C1-C6)烷基、-CO(C1-C6)卤代烷基、-CO-芳基、-CO-杂芳基、-CO-杂环基、4至7元杂环、7至14元双环杂环体系、任选地具有一个或多个杂原子的桥环或螺环体系;在实施方案中,R’和R”任选地形成4至7元杂环体系。
R2选自以下环体系
其中X、Y、Z在每次出现时独立地表示C、N、S、SO2和O,其可以被任选地取代;
R7、R8、R9、R10、R11和R12中的每一个在每次出现时独立地选自氢,卤素,氰基,酰胺,磺酰胺,酰基,羟基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C3-C6)环烷基、(C1-C6)烷氧基、苄基、芳基、杂芳基、杂环基;在一个实施方案中,R8和R9、R9和R10、R10和R11以及R11和R12在可能的情况下各自可以一起形成含有0个至2个选自N、O和S(O)p的另外的杂原子的4至7元饱和的或部分饱和的环;p=1至2。
Rx和Ry在每次出现时独立地选自氢、卤素、任选取代的选自(C1-C6)烷基的基团;或者,Rx和Ry可以一起形成4至7元杂环体系;
‘M’选自芳基、杂芳基、杂环基;
当上述定义的基团中的任一个被取代时,其上的取代可选自上述的那些或可以选自氢,羟基,氰基,卤代,卤代烷基,卤代烷氧基,烷硫基,任选取代的选自以下的基团:(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、(C3-C10)环烷基、C1-C6烷氧基、芳基、杂环基、杂芳基、-COR11、-CSR11、C(O)OR11、C(O)-R11、-C(O)-NR11R12、-C(S)-NR11R12、-SO2R11基团,其中R11和R12中的每一个独立地选自氢,任选取代的选自以下的基团:(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、(C3-C7)环烷基、芳基、杂芳基、杂环基基团;
在优选实施方案中,以上描述的基团(groups)、基团(radicals)可以选自:
“烷基”以及具有前缀“烷”的其它基团,例如烷氧基和烷酰基,意指如技术人员所熟知的,其可进一步被氧原子取代的碳链,其可进一步是直链或支链的及其组合,除非碳链另有定义。烷基基团的实例包括但不限于甲基、乙基、丙基、异丙基、丁基、仲丁基、叔丁基、戊基、己基等,在指定的碳原子数允许的情况下,例如C3-10,术语烷基还包括环烷基,以及与环烷基结构组合的直链或支链烷基链的组合。当没有指定碳原子数时,意指C1-6。取代的烷基包括被一个或多个选自以下的部分取代的烷基:卤代(例如,Cl、F、Br和I);卤代烷基(例如,CF3、2-Br-乙基、CH2F、CH2Cl、CH2CF3或CF2CF3);羟基;氨基;羧酸酯;酰胺基;烷基氨基;芳基氨基;烷氧基;芳氧基;硝基;叠氮基;氰基;硫代;磺酸;硫酸酯;膦酸;磷酸酯和膦酸酯以及在“任选取代的”的定义下描述的那些。
“烯基”意指含有至少一个碳-碳双键的碳链,并且其可以是直链的或支链的或其组合,除非碳链另有定义。烯基的实例包括但不限于乙烯基、烯丙基、异丙烯基、己烯基、戊烯基、庚烯基、1-丙烯基、2-丁烯基、2-甲基-2-丁烯基等,在指定的碳原子数允许的情况下,例如C5-10,术语烯基还包括环烯基以及直链、支链和环状结构的组合。当没有指定碳原子数时,意指C2-6)。
“炔基”意指含有至少一个碳-碳叁键的碳链,并且其可以是直链的或支链的或其组合。炔基的实例包括乙炔基、炔丙基、3-甲基-1-戊炔基等。当没有指定碳原子数时,意指。
单独使用或与其它基团组合使用的“硫代烷基”基团表示与式-SR’(硫及其氧化形式)(其中R’表示氢、烷基或芳基基团)的基团连接的如上所定义的烷基基团,例如硫代甲基、甲基硫代甲基、苯基硫代甲基等,其可以任选地被取代。
如本文所用,“碳环”或“碳环残基”旨在意指任何稳定的单环或双环或三环,其中任一个可以是饱和的、部分不饱和的或芳香族的。此类碳环的实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、金刚烷基、环辛基、[3.3.0]二环辛烷、[4.3.0]二环壬烷、[4.4.0]二环癸烷(十氢化萘)、[2.2.2]二环辛烷、芴基、苯基、萘基、茚满基、金刚烷基或四氢萘基(四氢化萘)。在更广泛的观点中,术语碳环旨在包括(在适用的情况下)表示环烷基、苯基以及其它饱和、部分饱和或芳香族的残基的基团;
术语“环烷基”和“环烯基”是指任选取代的、饱和的和不饱和的单环、双环或三环碳基团。在适当的情况下,环烷基或环烯基基团可以具有指定的碳原子数,例如,C3-C6环烷基或环烯基在其范围内包括具有3、4、5或6个碳原子的碳环基团。此类取代基的实例可选自环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基等。取代的环烷基或环烯基包括被一个或多个选自以下的部分取代:卤代(例如,Cl、F、Br和I);卤代烷基(例如,CF3、2-Br-乙基、CH2F、CH2Cl、CH2CF3或CF2CF3);羟基;氨基;羧酸酯;酰胺基;烷基氨基;芳基氨基;烷氧基;芳氧基;硝基;叠氮基;氰基;硫代;磺酸;硫酸酯;膦酸;磷酸酯和膦酸酯以及在“任选取代的”的定义下描述的那些。
“烷氧基”是指指定碳原子数的直链或支链烷氧化物。
“芳基”意指含有碳环原子的单环或多环芳香族环体系。优选的芳基是单环或双环6至10元芳香族环体系。苯基和萘基是优选的芳基。
“杂环基”是指饱和的、部分饱和的或不饱和的芳族或非芳族的单环、双环或三环基团,其含有一个或多个选自氮、硫和氧的杂原子,进一步任选地包括硫的氧化形式,即SO&SO2。杂环基体系可以通过该基团的任何数目的碳原子或杂原子连接到另一部分,并且可以是饱和的和不饱和的。杂环的实例包括四氢呋喃(THF)、二氢呋喃、1,4-二氧六环、吗啉、1,4-二噻烷、哌嗪、哌啶、1,3-二氧戊环、咪唑啉、咪唑烷、吡咯烷、吡咯啉、四氢吡喃、二氢吡喃、氧硫杂环戊烷、二硫杂环戊烷、1,3-二氧六环、1,3-二噻烷、氧硫杂环己烷、硫代吗啉等。术语“杂环烷基”是指与如上文所定义的烷基基团连接的如上文所定义的杂环基团;
“杂芳基”意指含有至少一个选自O、S和N的环杂原子的芳香族或部分芳香族的杂环。因此,杂芳基包括与其它种类的环,例如芳基、环烷基和非芳香族的杂环稠合的杂芳基。杂芳基基团的实例包括:吡咯基、异噁唑基、异噻唑基、吡唑基、吡啶基、噁唑基、噁二唑基、噻二唑基、噻唑基、咪唑基、三唑基、四唑基、呋喃基、三嗪基、噻吩基、嘧啶基、苯并异噁唑基、苯并噁唑基、苯并噻唑基、苯并噻二唑基、二氢苯并呋喃基、吲哚啉基、哒嗪基、吲唑基、异吲哚基、二氢苯并噻吩基、吲哚啉基、哒嗪基、吲唑基、异吲哚基、二氢苯并噻吩基、吲哚嗪基、噌啉基、酞嗪基、喹唑啉基、萘啶基、咔唑基、苯并二氧戊环基、喹喔啉基、嘌呤基、呋吖基、异苄基呋喃基、苯并咪唑基、苯并呋喃基、苯并噻吩基、喹啉基、吲哚基、异喹啉基、二苯并呋喃基等。对于杂环基和杂芳基基团,包括含有形成1至3个环的3至15个碳原子的环和环体系。
术语“卤代烷基”意指其中至少一个氢被卤素原子替代的烷基结构。在其中两个或更多个氢原子被卤素原子替代的某些实施方案中,卤素原子全部彼此相同。
“卤代烷氧基”基团选自与氧原子直接连接的如上文所定义的合适的卤代烷基,更优选选自氟甲氧基、氯甲氧基、氟乙氧基、氯乙氧基等的基团;
在其中两个或更多个氢原子被卤素原子替代的某些其它实施方案中,卤素原子并非全部彼此相同。
“芳氧基烷基”意指被如本文所定义的芳氧基基团取代的烷基基团。
“芳氧基芳基”意指被如本文所定义的芳氧基基团取代的芳基基团。
“芳氧基杂芳基”意指被如本文所定义的芳氧基基团取代的杂芳基基团。
“卤代/卤素”是指氟、氯、溴、碘。通常优选氯和氟。
在这些基团上的合适的基团和取代基可以选自在说明书中任何地方描述的那些。
如本文所用的术语“取代的”意指指定原子上的任一个或多个氢被选择的指定基团替代,条件是不超过指定原子的正常化合价,并且取代产生稳定的化合物。如本文所用的术语“取代的”意指指定原子上的任一个或多个氢被选择的指定基团替代,条件是不超过指定原子的正常化合价,并且取代产生稳定的化合物。
“药物可接受的盐”是指所公开的化合物的衍生物,其中母体化合物通过制备其酸或碱盐而被修饰。药物可接受的盐的实例包括但不限于碱性残基的无机或有机酸盐。此类常规无毒盐包括但不限于衍生自无机酸和有机酸的那些盐,所述无机酸和有机酸选自1,2-乙二磺酸、2-乙酰氧基苯甲酸、2-羟基乙磺酸、乙酸、抗坏血酸、苯磺酸、苯甲酸、重碳酸、碳酸、柠檬酸、乙二胺四乙酸、乙二磺酸、乙磺酸、富马酸、葡庚糖酸、葡糖酸、谷氨酸、乙醇酸、乙醇胂酸(glycollyarsanilic)、己基间苯二甲酸(hexylresorcinic)、肼基乙酸、氢溴酸、盐酸、氢碘酸、羟基马来酸、羟基萘甲酸、羟乙基磺酸、乳酸、乳糖酸、-月桂基磺酸、马来酸、苹果酸、扁桃酸、甲磺酸、萘磺酸、硝酸、草酸、双羟萘酸、泛酸、苯乙酸、磷酸、聚半乳糖醛酸、丙酸、水杨酸、硬脂酸、次乙酸、琥珀酸、氨基磺酸、对氨基苯磺酸、硫酸、鞣酸、酒石酸和甲苯磺酸。
术语“任选的”或“任选地”意指随后描述的事件或情形可能发生或可能不发生,并且该描述包括该事件或情形发生的情况以及该事件或情形不发生的情况。例如,任选取代的烷基是指“烷基”或“取代的烷基”。此外,任选取代的基团包括未取代的基团。
除非在说明书中另有说明,本文描述的结构还意指包括区别仅在于一个或多个同位素富集的原子的存在的化合物。
特别有用的化合物可以选自但不限于以下:
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-5-(2-羟基丙-2-基)噻吩-2-磺酰亚胺酰胺;
N'-氰基-4-氟-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-3-(2-羟基丙-2-基)苯磺酰亚胺酰胺;
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-4-(2-羟基丙-2-基)呋喃-2-磺酰亚胺酰胺;
(E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(噻唑-2-基)乙烯磺酰胺;
(E)-2-(1-乙基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺;
(E)-2-(1-乙基-4-甲基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺;
(R,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-甲基吡咯烷-2-基)乙烯-1-磺酰胺;
(S,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺;
(R,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺;
(S,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺;
(S,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钾;
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(E)-N'-氰基-2-((S)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺;
(E)-N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-((R)-1-甲基吡咯烷-2-基)乙烯-1-磺酰亚胺酰胺;
(E)-N'-氰基-2-((R)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺;
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((1S,8aR)-3,3,8a-三甲基八氢吡咯并[1,2-a]吡嗪-1-基)甲磺酰胺;
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((4S,8aS)-2,3,3,8a-四甲基八氢吡咯并[1,2-a]吡嗪-4-基)甲磺酰胺;
(E)-3-(二甲基氨基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)丙-1-烯-1-磺酰胺;
(E)-((3-(二甲基氨基)-3-甲基丁-1-烯-1-基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(S,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
或以上任何化合物的药学上可接受的盐。
以下是在本发明化合物的制备的描述中使用的缩写列表:
μg:微克
1H NMR:质子核磁共振
bs:宽单峰
CDC13:氘代氯仿
CHC13:氯仿
d:二重峰
DAMP:损伤相关分子模式;
DBU:1,8-二氮杂双环(5.4.0)十一碳-7-烯
DCM:二氯甲烷
dd:双二重峰
DMAC:N,N-(二甲基乙酰胺)
DMAP:4-(二甲基氨基)吡啶
DMF:N,N-二甲基甲酰胺
DMSO:二甲基亚砜
dt:双三重峰
EDTA:乙二胺四乙酸
EtOAc:乙酸乙酯
EtOH:乙醇
HCl(g):氯化氢(气体)
IL1β:白细胞介素-1β
K2CO3:碳酸钾
m:多重峰
MeOH:甲醇
mmol:毫摩尔
MS:质谱
N2:氮气
Na2CO3:碳酸钠
ng:纳克
NIS:N-碘琥珀酰亚胺
PAMP:病原体相关分子模式;
PMA:佛波醇12-十四酸酯13-乙酸酯
POCI3:磷酰氯
RM:反应混合物
r.t.、RT:室温
s:单峰
t:三重峰
td:三二重峰
THF:四氢呋喃
TLC:薄层色谱
TLR:Toll样受体
TNFα:肿瘤坏死因子α
WT:野生型
A441V:丙氨酸441位至缬氨酸
E692K:谷氨酸692至赖氨酸
A439V:丙氨酸439位至缬氨酸
A441V:丙氨酸441位至缬氨酸
A439V:丙氨酸439位至缬氨酸
术语“药物组合物”是指本文所述的NLRP3拮抗剂或其他化合物与其他化学组分(本文统称为“赋形剂”)的混合物,赋形剂例如载体、稳定剂、稀释剂、分散剂、悬浮剂和/或增稠剂。该药物组合物促进NLRP3拮抗剂或其它化合物向生物体的施用。本领域中存在的施用化合物的多种技术,包括但不限于直肠施用、口服施用和静脉施用、气雾剂施用和胃肠外施用、眼部施用、肺部施用和局部施用。
在实施方案中,本发明提供用于治疗和预防冷吡啉相关周期性综合征(CAPS)的有效量的式(I)化合物或其药学上可接受的盐,所述有效量可以选自1mg至500mg;优选地1mg至250mg并且更优选地1mg至150mg。
在某些其它实施方案中,化合物以在每天提供约1mg至约50mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约100mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约150mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约200mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约250mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约300mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约350mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约400mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约450mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约500mg的式(I)化合物或其药学上可接受的盐的量口服施用至对象。
在实施方案中,本发明提供有效量的式(I)化合物或其药学上可接受的盐可以通过口服、局部、肠胃外、静脉内或肌内给药途径施用。在优选的实施方案中,本发明提供有效量的式(I)或其药学上可接受的盐通过口服途径施用。
式(I)的化合物或其药学上可接受的盐可以每日、每周向对象提供,如由医师向有需要的人开处方。
在另一实施方案中,本发明提供治疗患有冷吡啉相关周期性综合征(CAPS)的对象的方法,其包括用式(I)化合物或其药学上可接受的盐或含有它们的适合的药物组合物治疗需要这种治疗的患者。
在一种实施方案中,本发明提供式(I)化合物及其药学上可接受的盐与其他适合的试剂的组合,作为用于治疗冷吡啉相关周期综合征(CAPS)的治疗剂。
在一种实施方案中,所使用的另外的治疗剂选自:白细胞介素-1β的抑制剂(例如,利纳西普(Rilonacept)、卡那单抗(Canakinumab)和阿那白滞素(anakinra);免疫抑制剂(例如,甲氨蝶呤、巯基嘌呤、环磷酰胺)、代谢紊乱药物、糖皮质激素、非甾体抗炎药、Gasdermin D抑制剂(例如,死磺胺(Necrosulfonamide));Cox-2特异性抑制剂、TNF-α结合蛋白(例如,英夫利西单抗(infliximab)、依那西普(Etanercept))、干扰素-13、干扰素、白细胞介素-2、抗组胺药、β-激动剂、BTK抑制剂、抗胆碱(anticolinergics)、抗癌药;抗病毒药物,例如:瑞德西韦、洛匹那韦/利托那韦、法匹拉韦、莫诺拉韦、达菲;抗疟疾药,例如:氯醌(Choloroquinone)、羟基氯醌;或其适合的药学上可接受的盐。与以下组合使用的实例:非酒精性脂肪性肝炎(NASH)和纤维化药物;抗癌药;抗生素,例如阿奇霉素;激素、芳香化酶抑制剂、秋水仙碱、抗凝剂、抗体、细胞因子、抗IL6药物;抗寄生虫药;疫苗;干扰素;药物偶联物(drug conjugate);最初为SARS开发的药物(ACE2蛋白诱饵);静脉注射维生素C;丝裂原活化蛋白激酶信号传导抑制剂(ex:BAY 43-9006);Syk抑制剂;mTOR抑制剂;抗体(利妥昔单抗(Rituxan));和BCR/ABL拮抗剂。
在另一实施方案中,式(I)化合物以药物组合物的形式提供。
在实施方案中,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐的药物组合物,其中式(I)化合物是
在实施方案中,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物和适合的药学上可接受的赋形剂的药物组合物。
药学上可接受的赋形剂可以选自稀释剂、载体、粘合剂、崩解剂、润滑剂、表面活性剂等中的至少一种。
在实施方案中,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐的药物组合物,其中式(I)化合物或其药学上可接受的盐的有效量可以选自1mg至500mg;优选地1mg至250mg,更优选地1mg至150mg。
在实施方案中,本发明提供包含式(I)化合物或其药学上可接受的盐的药物组合物可以通过口服、局部、肠胃外、静脉内或肌内施用途径施用。在优选的实施方案中,药物组合物可以通过口服施用途径施用。
在本发明的另一实施方案中,提供了用于制备式(I)化合物的稳定药物组合物的方法。
稳定的药物组合物可以通过本领域技术人员已知的技术通过干式混合、湿法造粒或干法造粒方法来制备。因此,例如,
在湿法造粒工艺中,将药物与一种或多种药用赋形剂混合,并如前所述用适合的结合溶液造粒,以形成湿颗粒,将湿颗粒干燥并任选地过筛。将干燥的颗粒与一种或多种其他地方描述的合适赋形剂混合,然后压缩成片剂或填充至胶囊中。
在干式混合工艺中,将药物与所需的所有药用赋形剂混合。将共混物与一种或多种其他地方描述的合适赋形剂混合,然后将最终共混物压制成片剂或填充至胶囊中。
在干法造粒工艺中,将药物与一种或多种药用赋形剂混合,并压缩成丸,并且使这些丸通过所需的筛。将过筛的颗粒与一种或多种其他地方描述的合适赋形剂混合,然后压缩成片剂或填充至胶囊中。
在制剂中使用的一种或多种溶剂或媒介物选自水、丙酮、氯仿、二氯甲烷、乙醇、乙酸乙酯、甲醇、异丙醇及其组合以及本领域普通技术人员已知的其他此类材料。
在另一实施方案中,本发明提供式(I)化合物及其药学上可接受的盐单独或与其他适合的试剂组合作为用于治疗冷吡啉相关周期性综合征(CAPS)的治疗剂的施用。
在一种实施方案中,所使用的另外的治疗剂选自:白细胞介素-1β的抑制剂(例如,利纳西普、卡那单抗和阿那白滞素;免疫抑制剂(例如,甲氨蝶呤、巯基嘌呤、环磷酰胺)、代谢紊乱药物、糖皮质激素、非甾体抗炎药、Gasdermin D抑制剂(例如,死磺胺);Cox-2特异性抑制剂、TNF-α结合蛋白(例如,英夫利西单抗、依那西普)、干扰素-13、干扰素、白细胞介素-2、抗组胺药、β-激动剂、BTK抑制剂、抗胆碱、抗癌药;抗病毒药物,例如:瑞德西韦、洛匹那韦/利托那韦、法匹拉韦、莫诺拉韦、达菲;抗疟疾药,例如:氯醌、羟基氯醌;或其适合的药学上可接受的盐。与以下组合使用的实例:非酒精性脂肪性肝炎(NASH)和纤维化药物;抗癌药;抗生素,例如阿奇霉素;激素、芳香化酶抑制剂、秋水仙碱、抗凝剂、抗体、细胞因子、抗IL6药物;抗寄生虫药;疫苗;干扰素;药物偶联物;最初为SARS开发的药物(ACE2蛋白诱饵);静脉注射维生素C;丝裂原活化蛋白激酶信号传导抑制剂(ex:BAY 43-9006);Syk抑制剂;mTOR抑制剂;抗体(利妥昔单抗(Rituxan));以及BCR/ABL拮抗剂。
本发明的组合物也可与其他活性成分组合使用。为了治疗沙粒病毒(Arenaviridade virus)感染,优选地,另一种活性治疗剂对沙粒病毒感染、特别是拉沙病毒(Lassa virus)和胡宁病毒(Junin virus)感染具有活性。这些其他活性治疗剂的非限制性实例是利巴韦林、法匹拉韦(也称为T-705或Avigan)、T-705单磷酸盐、T-705-二磷酸盐、T-703三磷酸盐、ST-193及其混合物。
本发明的化合物和组合物也旨在伴随提供给患有沙粒病毒感染的患者的一般护理使用,所述一般护理包括胃肠外液体(包括葡萄糖盐水和林格氏乳酸盐)和营养、抗生素(包括甲硝唑和头孢菌素类抗生素,如头孢曲松和头孢呋辛)和/或抗真菌预防,解热镇痛药物、止吐药(如甲氧氯普胺)和/或止泻药、维生素和矿物质补充剂(包括维生素C或/和K和硫酸锌)、抗炎药(如布洛芬)、止痛药物和治疗患者群体中其他常见疾病的药物,例如抗疟疾药物(包括蒿甲醚和青蒿琥酯-苯芴醇(Artesunate-lumefantrine)组合疗法)、伤寒药(包括喹诺酮类抗生素,如环丙沙星,大环内酯类抗生素,例如阿奇霉素,头孢菌素类抗生素,诸如头孢曲松,或氨基青霉素,如氨苄青霉素)或志贺菌病。
本发明进一步公开了所述式(I)化合物或其适合的药物组合物用于治疗冷吡啉相关周期性综合征(CAPS)的用途。
在另一实施方案中,本发明提供了使用式(I)化合物或其药学上可接受的盐的药物组合物治疗冷吡啉相关周期性综合征(CAPS)的方法。在优选的实施方案中,使用式(I)化合物或其药物组合物治疗冷吡啉相关周期性综合征(CAPS)的方法。
在优选的实施方案中,本发明提供适用于治疗冷吡啉相关周期性综合征(CAPS)的式(11)化合物或其药学上可接受的盐。
在进一步优选的实施方案中,本发明提供式(11)化合物或其适合的药物组合物用于治疗冷吡啉相关周期性综合征(CAPS)的用途。
该方法包括向对象施用有效量的根据式(11)的化合物,
在另一优选实施方案中,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的有效量的式(11)化合物或其药学上可接受的盐,所述有效量可以选自1mg至500mg;优选地1mg至250mg,更优选地1mg至150mg。
在某些其它实施方案中,化合物以在每天提供约1mg至约50mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约100mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约150mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约200mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约250mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约300mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约350mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约400mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约450mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。在某些实施方案中,化合物以在每天提供约1mg至约500mg的式(11)化合物或其药学上可接受的盐的量口服施用至对象。。
在另一优选实施方案中,本发明提供有效量的式(11)化合物或其药学上可接受的盐可以通过口服、局部、肠胃外、静脉内或肌内给药途径施用。在优选的实施方案中,本发明提供有效量的式(11)或其药学上可接受的盐通过口服途径给药。
式(11)的化合物或其药学上可接受的盐可以每日、每周向对象提供,如由医师向有需要的人开处方。
在一种优选实施方案中,本发明提供式(11)化合物及其药学上可接受的盐与其他适合的试剂的组合,作为用于治疗冷吡啉相关周期性综合征(CAPS)的治疗剂。
其中其他适合的治疗剂可以选自:白细胞介素-1β的抑制剂(例如,利纳西普、卡那单抗和阿那白滞素;免疫抑制剂(例如,甲氨蝶呤、巯基嘌呤、环磷酰胺)、代谢紊乱药物、糖皮质激素、非甾体抗炎药、Gasdermin D抑制剂(例如,死磺胺);Cox-2特异性抑制剂、TNF-α结合蛋白(例如,英夫利西单抗、依那西普)、干扰素-13、干扰素、白细胞介素-2、抗组胺药、β-激动剂、BTK抑制剂、抗胆碱、抗癌药;抗病毒药物,例如:瑞德西韦、洛匹那韦/利托那韦、法匹拉韦、莫诺拉韦、达菲;抗疟疾药,例如:氯醌、羟基氯醌;或其适合的药学上可接受的盐。与以下组合使用的进一步实例也可以与式(11)的化合物组合用于治疗冷吡啉相关周期性综合征(CAPS):非酒精性脂肪性肝炎(NASH)和纤维化药物;抗癌药;抗生素,例如阿奇霉素;激素、芳香化酶抑制剂、秋水仙碱、抗凝剂、抗体、细胞因子、抗IL6药物;抗寄生虫药;疫苗;干扰素;药物偶联物;最初为SARS开发的药物(ACE2蛋白诱饵);静脉注射维生素C;丝裂原活化蛋白激酶信号传导抑制剂(ex:BAY 43-9006);Syk抑制剂;mTOR抑制剂;抗体(利妥昔单抗);以及BCR/ABL拮抗剂。
在优选的实施方案中,本发明提供了用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(11)化合物或其药学上可接受的盐的药物组合物。
在另一优选实施方案中,本发明提供了用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(11)化合物和适合的药学上可接受的赋形剂的药物组合物。
药学上可接受的赋形剂可以选自稀释剂、载体、粘合剂、崩解剂、润滑剂、表面活性剂等中的至少一种。
在另一优选实施方案中,本发明提供了用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(11)化合物、其药学上可接受的盐和任选地其他适合的治疗剂的药物组合物。
其中其他适合的治疗剂可以选自:白细胞介素-1β的抑制剂(例如,利纳西普、卡那单抗和阿那白滞素;免疫抑制剂(例如,甲氨蝶呤、巯基嘌呤、环磷酰胺)、代谢紊乱药物、糖皮质激素、非甾体抗炎药、Gasdermin D抑制剂(例如,死磺胺);Cox-2特异性抑制剂、TNF-α结合蛋白(例如,英夫利西单抗、依那西普)、干扰素-13、干扰素、白细胞介素-2、抗组胺药、β-激动剂、BTK抑制剂、抗胆碱、抗癌药;抗病毒药物,例如:瑞德西韦、洛匹那韦/利托那韦、法匹拉韦、莫诺拉韦、达菲;抗疟疾药,例如:氯醌、羟基氯醌;或其适合的药学上可接受的盐。与以下组合使用的进一步实例也可以与式(11)的化合物组合用于治疗冷吡啉相关周期性综合征(CAPS):非酒精性脂肪性肝炎(NASH)和纤维化药物;抗癌药;抗生素,例如阿奇霉素;激素、芳香化酶抑制剂、秋水仙碱、抗凝剂、抗体、细胞因子、抗IL6药物;抗寄生虫药;疫苗;干扰素;药物偶联物;最初为SARS开发的药物(ACE2蛋白诱饵);静脉注射维生素C;丝裂原活化蛋白激酶信号传导抑制剂(ex:BAY 43-9006);Syk抑制剂;mTOR抑制剂;抗体(利妥昔单抗);以及BCR/ABL拮抗剂。
在实施方案中,本发明提供用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(11)化合物或其药学上可接受的盐的药物组合物,其中式(11)化合物或其药学上可接受的盐的有效量可以选自1mg至500mg;优选地1mg至250mg,更优选地1mg至150mg。
在另一实施方案中,本发明进一步公开了所述式(11)化合物或其适合的药物组合物用于治疗冷吡啉相关周期性综合征(CAPS)的用途。
在另一实施方案中,本发明提供式(11)化合物的用途,其中该化合物以选自1mg至500mg、优选地选自1mg至250mg、更优选地选自1mg至150mg的每日剂量范围施用。
在另一优选实施方案中,本发明提供了使用式(11)化合物或其药学上可接受的盐的药物组合物治疗冷吡啉相关周期性综合征(CAPS)的方法。在优选实施方案中,使用式(11)化合物或其药物组合物治疗冷吡啉相关周期性综合征(CAPS)的方法。
在本发明的另一个优选的实施方案中,提供制备式(11)化合物的稳定药物组合物的方法。
可以通过本领域技术人员已知的技术通过干式混合、湿法造粒或干法造粒方法制备稳定的药物组合物。因此,例如,
在湿法造粒工艺中,将药物与一种或多种药用赋形剂混合,并如前所述用合适的结合溶液造粒,以形成湿颗粒,将湿颗粒干燥并任选地过筛。将干燥的颗粒与一种或多种其他地方描述的合适赋形剂混合,然后压缩成片剂或填充至胶囊中。
在干式混合工艺中,将药物与所需的所有药用赋形剂混合。将共混物与一种或多种其他地方描述的合适赋形剂混合,然后将最终共混物压制成片剂或填充至胶囊中。
在干法造粒工艺中,将药物与一种或多种药用赋形剂混合,并压缩成丸,并且使这些丸通过所需的筛。将过筛的颗粒与一种或多种其他地方描述的合适赋形剂混合,然后压缩成片剂或填充至胶囊中。
在制剂中使用的一种或多种溶剂或媒介物选自水、丙酮、氯仿、二氯甲烷、乙醇、乙酸乙酯、甲醇、异丙醇及其组合和本领域普通技术人员已知的其它此类材料。
在实施方案中,本发明中描述的药学上可接受的赋形剂选自稀释剂、载体、粘合剂、崩解剂、润滑剂、表面活性剂等中的至少一种。
稀释剂包括但不限于乳糖一水合物、选自尤特奇(Eudragit)的聚甲基丙烯酸酯、氯化钾、磺丁基醚β-环糊精、氯化钠和喷雾干燥的乳糖,其组合和本领域普通技术人员已知的其它此类材料。
载体包括但不限于乳糖、白糖、氯化钠、葡萄糖、尿素、淀粉、碳酸钙和高岭土、结晶纤维素和硅酸,其组合和本领域普通技术人员已知的其它此类材料。
粘合剂包括但不限于选自卡波普(carbopol)的卡波姆、结冷胶、阿拉伯树胶、氢化植物油,选自尤特奇的聚甲基丙烯酸酯、黄原胶、乳糖和玉米醇溶蛋白,其组合以及本领域普通技术人员已知的其它此类材料。
崩解剂包括但不限于碳酸氢盐、甲壳素、结冷胶、波拉克林钾和多库酯钠,其组合和本领域普通技术人员已知的其它此类材料。
使用的润滑剂包括但不限于山嵛酸甘油酯、氢化植物油、硬脂酰富马酸钠和肉豆蔻酸,其组合和本领域普通技术人员已知的其它此类材料。
表面活性剂包括但不限于选自烷基聚葡糖苷、椰油酰胺DEA、椰油酰胺MBA、椰油酰胺TEA、癸基麦芽糖苷和辛基葡糖苷的非离子表面活性剂;选自花生酸(arachnidan acid)和花生四烯酸的阴离子表面活性剂;选自十六烷基三甲基溴化铵和氯化十六烷基吡啶的阳离子表面活性剂;其组合和本领域普通技术人员已知的其它此类材料。
用于制备的一般方法
本发明的新化合物可以使用以下描述的反应和技术,以及有机合成领域技术人员已知的常规技术或本领域技术人员所理解的其变化形式来制备。
反应可以在适于所用试剂和材料且适于受影响进行转化的溶剂中进行。优选的方法包括但不限于以下描述的那些方法,其中所有符号如前文所定义,除非以下另有定义。
通式(I)的化合物可以如以下方案中所述连同在本领域技术人员的范围内适当的修改/变化来制备。
方案1
其中R1、R2、X和Y中的每一个如先前所定义。可以通过本领域技术人员熟悉的各种方法使用报道的步骤制备化合物1和化合物2。在合适的条件下,在碱(如氢化钠)和合适的溶剂的存在下,用异氰酸酯衍生物(2)处理化合物(1),得到式(I)的化合物。
进行如以上所述的方法步骤所需的具体反应条件、溶剂和其它参数都在本领域技术人员的能力范围内。
通过描述实施本发明的优选方式的以下非限制性实施例进一步说明本发明。这些不以任何方式限制本发明的范围。
实施例中给出的1H NMR光谱数据(见下文)使用400MHz光谱仪(Bruker AVANCE-400)记录并以δ标度报告。除非另有说明,用于NMR的溶剂是CDCl3,使用TMS作为内标。
实施例-1
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-5-(2-羟基丙-2-基)噻吩-2-磺酰亚胺酰胺
1H NMR(400MHz,DMSO-d6):δ=7.95(bs,1H),7.23(d,J=4.0Hz,1H),6.82(d,J=4.0Hz,1H),6.81(s,1H),5.63(s,2H),2.77(t,J=7.2Hz,4H),2.68–2.65(m,4H),1.94(qui,J=7.2Hz,4H),1.49(s,6H);MS(ESI):m/z(%)=445.10(100%)(M+H)+,443.10(100%)(M-H).
实施例2
N'-氰基-4-氟-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-3-(2-羟基丙-2-基)苯磺酰亚胺酰胺
1H NMR(400MHz,DMSO):δ=8.13(dd,J=2.4Hz,J=7.6Hz,1H),8.00(bs,1H),7.68-7.64(m,1H),7.24-7.19(m,2H),6.79(s,1H),2.76-2.60(m,8H),1.95-1.85(m,4H),1.50(s,3H),1.48(s,3H);MS(ESI):m/z(%)=456.88(100%)(M+H)+.
实施例-3
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-4-(2-羟基丙-2-基)呋喃-2-磺酰亚胺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.10(bs,1H),7.55(s,1H),6.82(s,1H),6.79(s,1H),5.03(s,1H),2.77(t,J=7.2Hz,4H),2.68(t,J=7.2Hz,4H),1.94(qui,J=7.2Hz,4H),1.38(s,6H);MS(ESI):m/z(%)=429.20(100%)(M+H)+,427.30(100%)(M-H).
实施例4
(E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(噻唑-2-基)乙烯磺酰胺
1H NMR(400MHz,DMSO-d6,D2O-X):δ=10.7(br,s,1H),8.23(s,1H),8.05(d,J=2.8Hz,1H),8.02(d,J=2.8Hz,1H),7.74(d,J=15.2Hz,1H),7.58(d,J=15.2Hz,1H),6.96(s,1H),2.79(t,J=7.2Hz,4H),2.66(t,J=6.8Hz,4H),1.98–1.91(m,4H);MS(ESI):m/z(%)=389.92(100%)(M+H)+,411.90(20%)(M+Na+).
实施例5
(E)-2-(1-乙基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺
1H NMR(400MHz,DMSO):δ=10.55(bs,1H),8.20(s,1H),7.46-7.42(m,2H),7.29(d,J=14.8Hz,1H),7.13(s,1H),6.95(s,1H),4.16(q,J=7.2Hz,2H),2.82-2.78(m,4H),2.67-2.64(m,4H),1.98-1.91(m,4H),4.16(t,J=7.2Hz,3H);MS(ESI):m/z(%)=401.15(100%)(M+H)+;423.15(50%)(M+Na)+.
实施例6
(E)-2-(1-乙基-4-甲基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺
1H NMR(400MHz,DMSO-d6):δ=10.55(s,1H),8.16(s,1H),7.36(d,J=14.8Hz,1H),7.21(d,J=14.8Hz,1H),7.17(s,1H),6.95(s,1H),4.08(q,J=7.2Hz,2H),2.80(t,J=7.2Hz,4H),2.66(t,J=7.2Hz,4H),2.12(s,3H),1.98–1.91(m,4H),1.27(d,J=7.2Hz,3H);MS(ESI):m/z(%)=415.18(100%)(M+H)+.
实施例-7
(R,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.03(s,1H),6.92(s,1H),6.87(d,J=14.8Hz,1H),6.60-6.54(m,1H),3.27-3.16(m,3H),2.80(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.35-2.33(m,2H),2.09-1.94(m,6H),1.81-1.73(m,2H),1.03(t,J=7.2Hz,3H);MS(ESI):m/z(%)=404.20(100%)(M+H)+.
实施例-8
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(吡咯烷-2-基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=9.71(brs,1H),7.49(s,1H),6.95(d,J=15.2Hz,1H),6.80(s,1H),6.36(dd,J=7.2Hz,J=15.2Hz,1H),4.08–4.02(m,1H),3.18–3.03(m,2H),2.77(t,J=7.2Hz,4H),2.70(t,J=7.2Hz,4H),2.14–2.07(m,4H),2.03–1.80(m,6H),1.70–1.60(m,1H);MS(ESI):m/z(%)=376.10(100%)(M+H)+,374.05(100%)(M-1)。
实施例-9
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-甲基吡咯烷-2-基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=10.53(brs,1H),7.97(s,1H),6.92(s,1H),6.84(d,J=15.2Hz,1H),6.53(dd,J=7.6Hz,J=15.2Hz,1H),3.13–3.04(m,1H),3.05–2.92(m,1H),2.80(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.33–2.28(m,1H),2.26(s,3H),2.05–1.91(m,5H),1.79–1.72(m,2H),1.59–1.54(m,1H);MS(ESI):m/z(%)=390.17(100%)(M+H)+,388.07(30%)(M-1).
实施例-10
(S,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.03(s,1H),6.92(s,1H),6.87(d,J=14.8Hz,1H),6.60-6.54(m,1H),3.27-3.16(m,3H),2.80(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.35-2.33(m,2H),2.09-1.94(m,6H),1.81-1.73(m,2H),1.03(t,J=7.2Hz,3H);MS(ESI):m/z(%)=404.20(100%)(M+H)+.
实施例-11
(R,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.04(s,1H),6.93(s,1H),6.74(d,J=15.6Hz,1H),6.65(d,J=15.2Hz,1H),2.93–2.86(m,1H),2.80(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.19(s,3H),1.99–1.91(m,5H),1.80–1.69(m,4H),1.13(s,3H),MS(ESI):m/z(%)=404.16(100%)(M+H)+.
实施例-12
(S,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.04(s,1H),6.93(s,1H),6.73(d,J=15.2Hz,1H),6.65(d,J=15.2Hz,1H),2.80(t,J=7.2Hz,4H),2.68(t,J=7.2Hz,4H),2.20(s,3H),1.96(m,4H),1.72(m,4H),1.13(s,3H);MS(ESI):m/z(%)=404.25(100%)(M+1).
实施例-13
(S,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠
1H NMR(400MHz,DMSO-d6):δ=7.33(s,1H),6.77(s,1H),6.56(d,J=15.2Hz,1H),6.16(d,J=16Hz,1H),2.76(t,J=7.2Hz,4H),2.69(t,J=7.2Hz,4H),2.62(m,1H),2.08(s,3H),1.90(m,4H),1.72(m,4H),1.60(m,3H),1.01(s,3H);MS(ESI):m/z(%)=404.20(100%)(M+1).
实施例-14
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钾
1H NMR(400MHz,DMSO-d6):δ=7.33(s,1H),6.77(s,1H),6.58(d,J=15.6Hz,1H),6.18(d,J=15.6Hz,1H),2.77–2.72(m,5H),2.69(t,J=7.2Hz,4H),2.64–2.58(m,1H),2.08(s,3H),1.90(quin,J=7.6Hz,4H),1.75–1.70(m,3H),1.62–1.60(m,1H),1.01(s,3H);MS(ESI):m/z(%)=404.21(100%)(M-K)+.
实施例-15
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠
1H NMR(400MHz,DMSO-d6):δ=7.36(s,1H),6.77(s,1H),6.57(d,J=15.6Hz,1H),6.19(d,J=15.6Hz,1H),2.76(t,J=7.2Hz,5H),2.69(t,J=7.2Hz,4H),2.64–2.59(m,1H),2.08(s,3H),1.91(quin,J=7.6Hz,4H),1.74–1.68(m,3H),1.62–1.60(m,1H),1.01(s,3H);MS(ESI):m/z(%)=404.17(100%)(M-Na)+.
实施例-16
(E)-N'-氰基-2-((S)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺
1H NMR(400MHz,DMSO-d6):δ=9.94(s,1H),8.06(s,1H),6.97(d,J=16.0Hz,1H),6.83(s,1H),6.56–6.48(m,1H),3.58(br s,1H),3.24–3.12(m,1H),2.77(t,J=7.2Hz,4H),2.69(t,J=7.2Hz,7H),2.10–1.99(m,3H),1.95–1.88(m,5H),1.53–1.36(m,3H);ESI-Q-TOF-MS:m/z[M-HCl+H]+计算值[C22H30N5O2S]+:428.2120;实测值:428.2052
实施例-17
(E)-N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-((R)-1-甲基吡咯烷-2-基)乙烯-1-磺酰亚胺酰胺
1H NMR(400MHz,DMSO-d6):δ=9.82(s,1H),8.06(s,1H),7.11–7.02(m,1H),6.83(s,1H),6.43–6.35(m,1H),4.99(br s,1H),3.62–3.61(m,1H),3.09–3.07(m,1H),2.77(t,J=7.2Hz,7H),2.70(t,J=7.2Hz,4H),2.33–2.27(m,1H),2.1–1.88(m,7H);MS(TOF):m/z(%)=414.1897(100%)(M+H)+,412.1765(100%)(M-1)-.
实施例-18
(E)-N'-氰基-2-((R)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺
/>
1H NMR(400MHz,DMSO-d6):δ=9.98(s,1H),8.03(s,1H),6.94–6.90(m,1H),6.83(s,1H),6.54–6.51(m,1H),2.77(t,J=7.2Hz,5H),2.70(t,J=7.2Hz,5H),2.62(br s,3H),1.99–1.90(br s,2H),1.97–1.93(m,6H),1.48–1.46(m,3H);MS(TOF):m/z(%)=428.2097(100%)(M+H)+,426.1941(60%)(M-1)-.
实施例-19
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((1S,8aR)-3,3,8a-三甲基八氢吡咯并[1,2-a]吡嗪-1-基)甲磺酰胺
1H NMR(400MHz,DMSO-d6):δ=7.92(s,1H),6.87(s,1H),3.42-3.26(m,5H),3.07-3.01(m,1H),2.89-2.80(m,1H),2.89-2.80(m,1H),2.77(t,J=7.2Hz,4H),2.73-2.67(m,4H),2.58-2.44(m,1H),2.38-2.33(m,1H),1.98-1.92(m,4H),1.69-1.61(m,2H),1.31(s,3H),1.18(s,3H),0.78(s,3H);MS(TOF):m/z(%)=461.2537(100%)(M+H)+.
实施例-20
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((4S,8aS)-2,3,3,8a-四甲基八氢吡咯并[1,2-a]吡嗪-4-基)甲磺酰胺
1H NMR(400MHz,DMSO-d6):δ=8.03(s,1H),6.93(s,1H),3.52–3.48(m,2H),3.18–3.09(m,1H),3.09–3.01(m,1H),3.00–2.88(m,1H),2.81(t,J=7.2Hz,4H),2.70(t,J=7.2Hz,4H),2.36–2.33(m,2H),2.19(s,3H),2.01–1.93(m,4H),1.76–1.69(m,1H),1.67–1.54(m,3H),1.01–1.04(m,6H),0.86(s,3H);MS(TOF):m/z(%)=475.2709(100%)(M+H)+,473.2593(20%)(M-1).
实施例-21
(E)-3-(二甲基氨基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)丙-1-烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=10.22(brs,1H),7.94(s,1H),6.91(s,1H),6.86(d,J=15.2Hz,1H),6.62–6.55(m,1H),3.27(t,J=6.0Hz,2H),2.79(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.30(s,6H),1.99–1.91(m,4H);MS(ESI):m/z(%)=364.1513(100%)(M+H)+.
实施例-22
(E)-((3-(二甲基氨基)-3-甲基丁-1-烯-1-基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠
1H NMR(400MHz,DMSO-d6):δ=7.36(s,1H),6.77(s,1H),6.51(d,J=15.6Hz,1H),6.23(d,J=15.6Hz,1H),2.76(t,J=7.2Hz,4H),2.69(t,J=7.2Hz,4H),2.11(s,1H),1.94–1.87(m,4H),1.06(s,6H);MS(TOF):m/z(%)=392.1987(100%)(M+H)+,390.1841(20%)(M-1).
实施例-23
(S,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=7.93(s,1H),6.91(s,1H),6.71(d,J=15.2Hz,1H),6.60(d,J=15.6Hz,1H),2.85–2.83(m,1H),2.80(t,J=7.2Hz,4H),2.73–2.71(m,1H),2.67(t,J=7.2Hz,4H),2.15(s,2H),1.95(quin,J=7.2Hz,4H),1.81–1.69(m,4H),1.10(s,3H).ESI-Q-TOF-MS:m/z 405.2268(100%)[M+H]+,403.1901(100%)[M-H]-.
实施例-24
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=7.94(s,1H),6.91(s,1H),6.72(d,J=15.2Hz,1H),6.61(d,J=15.2Hz,1H),2.88–2.83(m,1H),2.80(t,J=7.2Hz,4H),2.75–2.71(m,1H),2.67(t,J=7.2Hz,4H),2.15(s,2H),1.95(quin,J=7.2Hz,4H),1.82–1.69(m,4H),1.11(s,3H),ESI-Q-TOF-MS:m/z 405.2104(100%)[M+H]+,403.1915(100%)[M-H]-.
实施例-25
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺
1H NMR(400MHz,DMSO-d6):δ=10.5(br s,1H),7.99(s,1H),6.92(s,1H),6.86(d,J=15.2Hz,1H),6.56(dd,J1=7.6Hz,J2=15.2Hz,1H),3.12–3.06(m,2H),2.80(t,J=7.2Hz,4H),2.67(t,J=7.2Hz,4H),2.38–2.32(m,1H),2.25(s,2H),2.08–2.01(m,1H),1.95(quin,J=7.2Hz,4H),1.80–1.73(m,2H),1.63–1.54(m,1H),ESI-Q-TOF-MS:m/z 391.1956(100%)[M+H]+,389.1756(100%)[M-H]-.
评估在健康志愿者中和对CAPS突变的效力的体外研究:
化合物11是一种强效NLRP3炎症小体抑制剂,其阻断来自激活的THP-1细胞、hPBMC(人外周血单核细胞)和用LPS(脂多糖)和ATP(三磷酸腺苷)处理的全血的IL-1β和IL-18分泌。对于全血测定,按照伦理委员会批准的方案,从健康志愿者采集人外周静脉血。将全血分布在96孔板中,并用LPS(500ng/mL)预处理4小时。在无血清培养基存在下加入不同浓度的化合物11。用ATP(5mM)诱导NLRP3炎症小体1小时。在1小时结束时收集上清液,并使用ELISA方法测定释放的IL-1β。绘制细胞因子水平的抑制,获得半数最大抑制浓度。
表1:化合物11对来自健康志愿者的PBMC中NLRP3介导的IL-1β释放的半数最大抑制浓度
全血检测(正常志愿者) | IC50(nM)平均值±SD* |
化合物11 | 186±32 |
*三名健康志愿者的平均数据
体外药效学评价
在体外药效学评价中,给药后在特定时间间隔抽取血液,并使用LPS和ATP诱导NLRP3。SAD和MAD研究中观察到测试的所有剂量对IL-1β分泌的抑制率均超过90%。ED90达到低于400ng/mL。
为了检验化合物11在CAPS条件下的效力,首先针对不同的CAPS突变测试化合物11的效力。当在正常志愿者中用LPS和ATP诱导或在CAPS患者志愿者中仅用LPS诱导时,含有单核细胞的人PBMC表达NLRP3。采用梯度法从志愿者分离人外周血单个核细胞(hPBMC)。在用LPS和/或ATP激活之前,将hPBMC悬浮在完全生长培养基中并铺板过夜。得到化合物11对用各自的刺激物激活并且随后用化合物11处理的正常志愿者PBMC和CAPS患者PBMC的半数最大抑制浓度。化合物11在分离自健康志愿者的PBMC中显示出3.0-6.0nM的IC50。当在5种不同的CAPS患者志愿者PBMC中测试时,化合物11显示出2.2nM至31.3nM的效力。有趣的是,化合物11的效力优于已发表的MCC950的报告,MCC950是其中在类似的突变家族中效力较低的竞争分子。在A439V突变中正面交锋,化合物11为15.1nM和31.3nM,MCC950显示IC50≥100nM。(Wellcome Open Research 2020,5:247)
表2:化合物11对来自健康志愿者和CAPS志愿者的PBMC中NLRP3介导的IL-1β释放的半数最大抑制浓度
*来自正常志愿者(NLRP3 WT)的PBMC用10ng LPS和5mM ATP刺激以激活炎症小体复合物,并测量分泌的IL-1β。来自CAPS患者志愿者(NLRP3突变体)的PBMC用100ng LPS刺激以激活炎症小体复合物,并测量分泌的IL-1β。
在1期单次递增剂量临床研究中,化合物11在健康志愿者的血浆水平中显示出良好的药代动力学特征,具有剂量依赖性调节。在多次递增BID研究中,化合物11也实现了剂量依赖性的稳态水平。
总之,在临床前研究和涉及具有野生型NLRP3的人类健康患者的研究中,化合物11在NLRP3介导的IL-1β抑制中显示出nM效力,在临床中也显示出完美的转化。有趣的是,其在已证实具有限定获得的NLRP3的功能突变的CAPS患者中在NLRP3介导的IL-1β抑制方面同样有效。
化合物11在健康成人对象中的功效:
方案标题:通过口服途径施用的化合物11的1期前瞻性研究,以研究在健康成人对象中的安全性、耐受性、药代动力学和药效学。
目标:
主要目标:
·评估向健康对象施用的化合物11的安全性和耐受性。
次要目标:
·表征化合物11当以单次口服剂量施用至健康对象时的药代动力学。
·评估化合物11在健康对象中的药效学特性。
探索性:
·分析和鉴定/量化在血浆和尿液中化合物11的独特代谢物。
·评估化合物11在健康对象中的任何其他药效学特性。
安全性标准:
·记录生命体征,如体温、血压、呼吸速率、SpO2和桡动脉脉搏。
·临床检查,包括一般检查以及全身检查(心血管系统(CVS)、呼吸系统(RS)、胃肠系统(GI)、中枢神经系统(CNS))
·ECG评估
·临床实验室测试(即血液学、血清生物化学、尿液分析和血清学)
·记录所有入选对象的不良事件(AE)的频率和严重程度。所有AE均使用以下进行分类:
■因果关系
■严重程度
■严重性
方法学:
这是非盲(open label)研究,旨在评估向健康对象单次口服剂量施用化合物11后的安全性、耐受性、药代动力学(PK)和药效学(PD)。
在该研究中,每组包含六名对象,以递增的方式给予单次口服剂量的化合物11。最初,多达3个组(包括25mg、50mg和100mg剂量)的18名对象入选并给药。中期分析是在完成三个组后进行的,并提交给中央许可机关(Central Licensing Authority)。
·治疗持续时间:单次给药
·如果对象健康,年龄在18岁至55岁(含),体重指数(BMI)在18.5kg/m2至30.0kg/m2(含两端值)之间,体重在50kg至100kg(含两端值)范围内,在筛查和登记时具有正常QTc间期[QTcF≤450ms],同意遵守试验程序,并愿意采取高效避孕措施,则有资格纳入研究。
·如果对象在过去3个月内有系统性病症/疾病的病史或存在;具有临床意义的超敏反应、不耐受或过敏的病史;14天内有COVID-19感染史或14天内与确诊的活性COVID-19阳性患者有接触;或者登记后5天内COVID-19检测呈阳性;收缩压大于140mmHg或小于100mmHg或舒张压大于90mmHg或小于60mmHg的对象;脉搏率小于55次/分钟或大于100次/分钟以及方案中定义的其他排除标准,则将其排除在研究之外。
·邀请这些对象参与本研究。
·根据活性图进行安全性和有效性评估。
治疗组对象的编号:共有18名对象入选,即每个组S1(25mg)、组S2(50mg)和组S3(100mg)中有6名对象。共有18名对象入选并服用该化合物胶囊。共有17名对象完成了研究。
治疗持续时间:对象在28天的筛选期内入选,口服单剂量的化合物11胶囊,并在给药后随访长达48小时。
结果
在18名入选对象中,有17名对象完成了研究。所有18名对象均为亚洲人,男性对象。总体而言,本研究的平均(范围)年龄为37岁(23至47岁),BMI为23.51kg/m2(19.71至28.01kg/m2)。在健康对象中,通过口服途径施用的化合物被发现是安全的并且直到100mg单剂量耐受性良好。没有对象因不良事件而退出研究。
药代动力学和药代动力学结果
药代动力学结果
使用单独验证的LC-MS/MS测定法分析血浆和尿液样品以估计化合物。对浓度-时间数据进行药代动力学参数评估。
组S1(25mg剂量)
总共6名健康男性对象接受了25mg剂量的化合物11。
注:组S1中的1名对象撤回了他的同意并退出了研究。因此,该对象未用于药代动力学评估。
药代动力学评估表明,该药物经口服吸收良好,达到最大血浆浓度的中值时间,即中值Tmax为1.500hr,在0.500hrs至2.000hrs范围内。平均消除半衰期为6.526±0.67hrs。平均Cmax和AUC0-t分别为3.393±0.72μg/mL和26.967±0.39hr*μg/mL。平均血浆清除率为0.922±0.01L/hr,平均分布体积为8681.147±929.14mL。未改变的化合物的平均累积尿回收百分比为93.26%。
组S2(50mg剂量)
总共6名健康男性对象接受了50mg剂量的化合物11。
药代动力学评估表明,该药物经口服吸收良好,达到最大血浆浓度的中值时间,即中值Tmax为1.000hr,在0.500hrs至2.000hrs范围内。平均消除半衰期为5.818±0.47hrs。平均Cmax和AUC0-t分别为5.724±0.52μg/mL和40.838±7.20hr*μg/mL。平均血浆清除率为1.238±0.22L/hr,并且平均分布体积为10285.52±1174.32mL。未改变的化合物的平均累积尿液回收百分比为69.09%。
组S3(100mg剂量)
总共6名健康男性对象接受了100mg剂量的化合物11。
药代动力学评估表明,该药物经口服吸收良好,达到最大血浆浓度的中值时间,即中值Tmax为1.000hr,在0.500hrs至1.500hrs的范围内。平均消除半衰期为6.275±0.65hrs。平均Cmax和AUC0-t分别为11.489±1.01μg/mL和92.302±14.90hr*μg/mL。平均血浆清除率为1.099±0.15L/hr,平均分布体积为9847.576±825.72mL。未改变的化合物的平均累积尿回收百分比为76.63%。
总体而言,化合物11表现出从胃肠道快速口服吸收,在1.0至1.5小时达到最大浓度。从25mg至100mg剂量观察到化合物11的暴露(Cmax&AUC)的剂量相关增加。三种剂量的平均消除半衰期为约6.0-6.5h。大部分未改变的化合物11被回收在尿液中,这表明肾脏是化合物排泄的主要途径。
药效学结果
在给药前、3小时、6小时、12小时和24小时分离的血液用LPS和ATP体外激活,并在LPS/ATP处理和未处理的全血中测量分泌的IL-1β和IL18。
按处理和时间点总结校正后的IL-1β全血浓度的描述性统计(n、平均值、标准差)。BLQ水平设置为0。校正后的IL-1β全血浓度由以下得出:(处理样品中的IL-1β浓度-未处理样品中的IL-1β浓度)。
IL-1β抑制的百分比计算为:[(给药前的处理浓度-给药前的未处理浓度)-(Rx时间点的处理浓度-Rx时间点的未处理浓度)]/(给药前的处理浓度-给药前的未处理浓度)*100%。
所有17名对象在施用化合物11后均显示出超过90%的IL-1β抑制。单剂量25mg、50mg和100mg的化合物11分别在给药后6小时、12小时和24小时显示出高于90%的体外IL-1β抑制。
Claims (32)
1.用于治疗冷吡啉相关周期性综合征(CAPS)的方法,其包括施用式(I)化合物或其药学上可接受的盐,
其中
X是O、NH或N-R3其中R3在每次出现时独立地选自氢,羟基,卤素,硝基,氰基,卤代烷基,任选取代的选自以下的基团:(C1-C10)烷基、(C1-C10)烷氧基、(C3-C10)环烷基、(C2-C10)烯基、(C2-C10)炔基、SO2(C1-C6)烷基、硫醇基、硫代烷基、硫代烷氧基、SO(C1-C6)烷基、苄基、芳基、杂芳基、杂环基;
Y是O、S;
R1在每次出现时独立地选自氢,卤素,卤代烷基,氰基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C2-C6)烯基、(C2-C6)炔基、(C1-C6)烷氧基、(C3-C7)环烷基、(C1-C6)烷基SO2(C1-C6)烷基、(C1-C6)烷基N(C1-C6)烷基、(C1-C6)烷基N(C3-C7)环烷基、芳基、杂芳基、杂环基、苄基、叔丁氧基羰基、NH(C1-C6)烷基、N((C1-C6)烷基)2、NH(C2-C6)烯基、N((C2-C6)烯基)2、-N-杂环基、N(C1-C6)烷基-杂环基、NR’R”、硫醇基、巯基烷基、SO2(C1-C6)烷基、SO2(C3-C7)环烷基、SO2-芳基、SO2-杂环基、(C1-C6)硫代烷基、(C1-C6)硫代烷氧基、(C1-C6)烷基SO2NH2、-CONH2、-CO(C1-C6)烷基、-CO(C1-C6)卤代烷基、-CO-芳基、-CO-杂芳基、-CO-杂环基、4至7元杂环、7至14元双环杂环体系、任选地具有一个或多个杂原子的桥环或螺环体系;
或者,R1选自
n独立地选自整数0至3;
R’、R”、R1’、R1”、R2’和R2”中的每一个在每次出现时独立地选自氢,卤素,卤代烷基,氰基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C2-C6)烯基、(C2-C6)炔基、(C1-C6)烷氧基、(C3-C7)环烷基、(C1-C6)烷基SO2(C1-C6)烷基、(C1-C6)烷基N(C1-C6)烷基、(C1-C6)烷基N(C3-C7)环烷基、芳基、杂芳基、杂环基、苄基、叔丁氧基羰基、硫醇基、巯基烷基、SO2(C1-C6)烷基、SO2(C3-C7)环烷基、SO2-芳基、SO2-杂环基、(C1-C6)硫代烷基、(C1-C6)硫代烷氧基、(C1-C6)烷基SO2NH2、-CONH2、-CO(C1-C6)烷基、-CO(C1-C6)卤代烷基、-CO-芳基、-CO-杂芳基、-CO-杂环基、4至7元杂环、7至14元双环杂环体系、任选地具有一个或多个杂原子的桥环或螺环体系;在实施方案中,R’和R”任选地形成4至7元杂环体系,
R2选自以下环体系
其中X、Y、Z在每次出现时独立地表示C、N、S、SO2和O,其可以被任选地取代;
R7、R8、R9、R10、R11和R12中的每一个在每次出现时独立地选自氢,卤素,氰基,酰胺,磺酰胺,酰基,羟基,任选取代的选自以下的基团:(C1-C6)烷基、(C1-C6)卤代烷基、(C3-C6)环烷基、(C1-C6)烷氧基、苄基、芳基、杂芳基、杂环基;在一个实施方案中,R8和R9、R9和R10、R10和R11以及R11和R12在可能的情况下各自可以一起形成含有0至2个选自N、O和S(O)p的另外的杂原子的4至7元饱和或部分饱和的环;p=1至2,
Rx和Ry在每次出现时独立地选自氢、卤素、任选取代的选自(C1-C6)烷基的基团;或者,Rx和Ry可以一起形成4至7元杂环体系;
‘M’选自芳基、杂芳基、杂环基;并且其中当上述定义的基团中的任一个被取代时,其上的取代选自上述的那些或可以选自氢,羟基,氰基,卤代,卤代烷基,卤代烷氧基,烷硫基,任选取代的选自以下的基团:
(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、(C3-C10)环烷基、C1-C6烷氧基、芳基、杂环基、杂芳基、-COR11、-CSR11、C(O)OR11、C(O)-R11、-C(O)-NR11R12、-C(S)-NR11R12、-SO2R11基团,其中R11和R12中的每一个独立地选自氢,任选取代的选自以下的基团:(C1-C6)烷基、(C2-C6)烯基、(C2-C6)炔基、(C3-C7)环烷基、芳基、杂芳基、杂环基基团。
2.如权利要求1所述的方法,其中所述式(I)化合物选自以下组:
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-5-(2-羟基丙-2-N'-氰基-4-氟-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-3-(2-羟基丙-2-基)苯磺酰亚胺酰胺;
N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-4-(2-羟基丙-2-基)呋喃-2-磺酰亚胺酰胺;
(E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(噻唑-2-基)乙烯磺酰胺;
(E)-2-(1-乙基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺;
(E)-2-(1-乙基-4-甲基-1H-咪唑-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯磺酰胺;
(R,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-甲基吡咯烷-2-基)乙烯-1-磺酰胺;
(S,E)-2-(1-乙基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-乙磺酰胺;
(R,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺;
(S,E)-2-(1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰胺;
(S,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钾;
(R,E)-((2-(1,2-二甲基吡咯烷-2-基)乙烯基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(E)-N'-氰基-2-((S)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺;
(E)-N'-氰基-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-((R)-1-甲基吡咯烷-2-基)乙烯-1-磺酰亚胺酰胺;
(E)-N'-氰基-2-((R)-1,2-二甲基吡咯烷-2-基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)乙烯-1-磺酰亚胺酰胺;
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((1S,8aR)-3,3,8a-三甲基八氢吡咯并[1,2-a]吡嗪-1-基)甲磺酰胺
N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-1-((4S,8aS)-2,3,3,8a-四甲基八氢吡咯并[1,2-a]吡嗪-4-基)甲磺酰胺;
(E)-3-(二甲基氨基)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)丙-1-烯-1-磺酰胺;
(E)-((3-(二甲基氨基)-3-甲基丁-1-烯-1-基)磺酰基)((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)酰胺钠;
(S,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(2-甲基-1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
(R,E)-N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨基甲酰基)-2-(1-(甲基-d)吡咯烷-2-基)乙烯-1-磺酰胺;
或以上任何化合物的药学上可接受的盐。
3.如权利要求1所述的方法,其中式(I)化合物或其药学上可接受的盐的治疗有效量选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg。
4.如权利要求1所述的方法,其中式(I)化合物或其药学上可接受的盐通过口服、局部或肠胃外施用途径施用,优选地通过口服施用途径施用。
5.如权利要求1所述的方法,其中式(I)化合物或其药学上可接受的盐与其它合适的治疗剂组合施用。
6.如权利要求1所述的方法,其中式(I)化合物或其药学上可接受的盐以药物组合物的形式施用。
7.如权利要求1或2所述的式(I)化合物用于制备用于治疗冷吡啉相关周期性综合征(CAPS)的药物的用途。
8.如权利要求1或2所述的式(I)化合物的用途,其中所述化合物以选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg的每日剂量范围施用。
9.用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(I)化合物或其药学上可接受的盐的药物组合物,其中式(I)化合物是
10.如权利要求9所述的药物组合物,其中式(I)化合物或其药学上可接受的盐的治疗有效量选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg。
11.如权利要求9所述的药物组合物,其包含式(I)化合物和其它药学上可接受的赋形剂,并用于治疗冷吡啉相关周期性综合征(CAPS)。
12.如权利要求9所述的药物组合物,其中式(I)化合物或其药学上可接受的盐与其它合适的治疗剂组合施用。
13.如权利要求9所述的药物组合物用于制备用于治疗冷吡啉相关周期性综合征(CAPS)的药物的用途。
14.用于治疗冷吡啉相关周期性综合征(CAPS)的方法,其包括施用式(11)化合物
或其药学上可接受的盐。
15.如权利要求14所述的方法,其中式(11)化合物或其药学上可接受的盐的治疗有效量选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg。
16.如权利要求14所述的方法,其中式(11)化合物或其药学上可接受的盐通过口服、局部或肠胃外施用途径施用,优选通过口服施用途径施用。
17.如权利要求14所述的方法,其中式(11)化合物或其药学上可接受的盐与其它合适的治疗剂组合施用。
18.如权利要求14所述的方法,其中式(11)化合物或其药学上可接受的盐以药物组合物的形式施用。
19.如前述权利要求中任一项所述的式(11)化合物用于制备用于治疗冷吡啉相关周期性综合征(CAPS)的药物的用途。
20.如前述权利要求中任一项所述的式(11)化合物的用途,其中所述化合物以选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg的每日剂量范围施用。
21.用于治疗冷吡啉相关周期性综合征(CAPS)的包含式(11)化合物或其药学上可接受的盐的药物组合物,其中式(11)化合物是
22.如权利要求21所述的药物组合物,其中式(11)化合物或其药学上可接受的盐的治疗有效量选自1mg至500mg,优选地选自1mg至250mg,更优选地选自1mg至150mg。
23.如权利要求21所述的药物组合物,其包含式(11)化合物和其它药学上可接受的赋形剂,并用于治疗冷吡啉相关周期性综合征(CAPS)。
24.如权利要求21所述的药物组合物,其中式(11)化合物或其药学上可接受的盐与其它合适的治疗剂组合施用。
25.如权利要求21所述的药物组合物用于制备用于治疗冷吡啉相关周期性综合征(CAPS)的药物的用途。
26.如权利要求21所述的药物组合物,其中其它药学上可接受的赋形剂选自稀释剂、载体、粘合剂、崩解剂、润滑剂和表面活性剂。
27.如前述权利要求中任一项所述的药物组合物,其中稀释剂选自乳糖一水合物,选自尤特奇的聚甲基丙烯酸酯、氯化钾、磺丁基醚β-环糊精、氯化钠和喷雾干燥的乳糖及其合适的组合。
28.如前述权利要求中任一项所述的药物组合物,其中载体选自乳糖、白糖、氯化钠、葡萄糖、尿素、淀粉、碳酸钙和高岭土、结晶纤维素、硅酸及其合适的组合。
29.如前述权利要求中任一项所述的药物组合物,其中粘合剂是选自卡波普(carbopol)的卡波姆、结冷胶、阿拉伯树胶、氢化植物油、选自尤特奇的聚甲基丙烯酸酯、黄原胶、乳糖和玉米醇溶蛋白及其合适的组合。
30.如前述权利要求中任一项所述的药物组合物,其中崩解剂选自碳酸氢盐、甲壳素、结冷胶、波拉克林钾、多库酯钠及其合适的组合。
31.如前述权利要求中任一项所述的药物组合物,其中润滑剂选自山嵛酸甘油酯、氢化植物油、硬脂酰富马酸钠、肉豆蔻酸及其合适的组合。
32.如前述权利要求中任一项所述的药物组合物,其中表面活性剂为选自烷基聚葡糖苷、椰油酰胺DEA、椰油酰胺MBA、椰油酰胺TEA、癸基麦芽糖苷和辛基葡糖苷的非离子表面活性剂;选自花生酸和花生四烯酸的阴离子表面活性剂;选自十六烷基三甲基溴化铵和氯化十六烷基吡啶的阳离子表面活性剂;以及其合适的组合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121030625 | 2021-07-08 | ||
IN202121030625 | 2021-07-08 | ||
PCT/IB2022/056329 WO2023281455A1 (en) | 2021-07-08 | 2022-07-08 | Treatment for cryopyrin associated periodic syndromes (caps) |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117940126A true CN117940126A (zh) | 2024-04-26 |
Family
ID=84801366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280059495.8A Pending CN117940126A (zh) | 2021-07-08 | 2022-07-08 | 用于冷吡啉相关周期性综合征(caps)的治疗 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4366832A1 (zh) |
CN (1) | CN117940126A (zh) |
AU (1) | AU2022305809A1 (zh) |
CA (1) | CA3226058A1 (zh) |
WO (1) | WO2023281455A1 (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3911631A4 (en) * | 2019-01-14 | 2022-09-28 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
-
2022
- 2022-07-08 WO PCT/IB2022/056329 patent/WO2023281455A1/en active Application Filing
- 2022-07-08 CN CN202280059495.8A patent/CN117940126A/zh active Pending
- 2022-07-08 CA CA3226058A patent/CA3226058A1/en active Pending
- 2022-07-08 EP EP22837147.2A patent/EP4366832A1/en active Pending
- 2022-07-08 AU AU2022305809A patent/AU2022305809A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4366832A1 (en) | 2024-05-15 |
CA3226058A1 (en) | 2023-01-12 |
WO2023281455A1 (en) | 2023-01-12 |
AU2022305809A1 (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI423976B (zh) | 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚 | |
EP3464266B1 (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
EP3224254B1 (de) | Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln | |
WO2019043610A1 (en) | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES | |
EP2338888A1 (en) | Imidazopyridine derivatives as JAK inhibitors | |
EP2397482A1 (en) | Heteroaryl imidazolone derivatives as jak inhibitors | |
JP2022527401A (ja) | 炎症性障害を治療するための化合物および方法 | |
BR112020026675A2 (pt) | Derivados de pirrolo[1,2-b]piridazina | |
WO2021111351A1 (en) | Novel substituted sulfonylurea and sulfoximineurea derivatives | |
JP2023506118A (ja) | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 | |
CN117940126A (zh) | 用于冷吡啉相关周期性综合征(caps)的治疗 | |
KR20090029261A (ko) | 신경계 장애의 치료에서의 트리플루오로메틸-치환 벤즈아미드의 용도 | |
EP4110058A1 (en) | Novel substituted sulfonylurea and sulfoximineurea derivatives | |
JP6010614B2 (ja) | 血清尿酸を低下させるための[1,2,4]チアジアジン1,1−ジオキサイド化合物 | |
KR20240052009A (ko) | 신경염증성 장애의 치료 | |
KR20080106226A (ko) | 신경계 장애의 치료에 있어서 피라졸로[1,5a]피리미딘-7-일 아민 유도체의 용도 | |
CN117321035A (zh) | 氘化的dhodh抑制剂 | |
WO2024023696A1 (en) | Dosing regimen for a nlrp3 inhibitor | |
CN113637019A (zh) | 一种选择性jak1抑制剂化合物及其制备方法和用途 | |
CN114746087A (zh) | 新的经取代的亚砜亚胺衍生物 | |
JP2021512927A (ja) | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |